OncoBone Ventures enters into collaboration with India-based Mestastop Solutions, a pioneer in the metastasis field. Mestastop has dissected the whole metastasis process in three patent protected platforms METAssay®, METSCAN® and METVivo® that they can use to identify cancer patients who are at a higher risk of metastasis, as well as pertinent targets for drug discovery.
Arnab and Debabani Roy Chowdhury, Founders and Directors of Mestastop state: “We were happy to partner with OncoBone Ventures, who are focused on developing novel therapies for cancer patients with bone metastases, for whom there are currently no effective therapies available. The collaboration includes developing novel in vitro models as a screening platform for evaluating efficacy of therapies on cancer bone metastases.”
Tiina Kähkönen, Founder and CSO of OncoBone Ventures comments: ‘We have been truly fortunate to find a collaborator like Mestastop Solutions who shares our passion to develop therapies for cancer patients with metastatic disease. Together we have the required expertise to successfully develop a pioneering in vitro bone metastasis platform that will be of great importance for the development of novel therapies affecting bone metastases.”
Jussi Halleen, Founder and CEO of OncoBone Ventures adds: “OncoBone Ventures aims to utilize the developed in vitro platform as a screening tool before testing efficacy of our pipeline assets in our current in vivo Bone Metastasis Technology Platform. This will lead to faster and more cost-effective development of efficient therapies for patients with bone metastases.”
More information about Mestastop Solutions in https://mestastop.com/.
If you are interested to learn more, please reach out via https://www.oncobonetherapeutics.com/contact-us/.